GVHDS
MCID: GRF003
MIFTS: 72

Graft-Versus-Host Disease (GVHDS)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Graft-Versus-Host Disease

MalaCards integrated aliases for Graft-Versus-Host Disease:

Name: Graft-Versus-Host Disease 56 36 54 37
Graft-Versus-Host Disease, Susceptibility to 56 29 39
Graft Versus Host Disease 74 58 54
Graft-Versus-Host Disease, Protection Against 56 13
Graft-Vs-Host Disease 71
Gvhds 56
Gvh 58

Characteristics:

Orphanet epidemiological data:

58
graft versus host disease
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare immunological diseases


Summaries for Graft-Versus-Host Disease

OMIM : 56 Transplantation of hematopoietic stem cells is a successful therapy for some tumors derived from bone marrow precursors, such as certain leukemias and lymphomas, and it can be used to cure some primary immunodeficiencies and inherited hematopoietic stem-cell diseases. One of the major complications of allogeneic bone marrow transplantation is graft-versus-host disease (GVHD), in which mature donor T cells that contaminate the allogeneic bone marrow recognize the tissues of the recipient as foreign, causing a severe inflammatory disease characterized by rashes, diarrhea, and liver disease. GVHD is particularly virulent when there is a mismatch of a major major histocompatibility complex (MHC) class I or class II antigen. Most transplants are therefore undertaken only when the donor and recipient are HLA-matched sibs or, less frequently, when there is an HLA-matched unrelated donor. However, GVHD also occurs in the context of disparities between minor histocompatibility antigens, and immunosuppression must be used in every stem-cell transplant (summary by Janeway et al., 2005). At the core of the immunogenetic basis for GVHD is the diversity of HLA, killer immunoglobulin-like receptors (KIRs; see 604936), and cytokine genes. HLA class I molecules function as ligands for natural killer cell inhibitory KIRs, indicating that GVHD results from a complex interplay between innate and adaptive immune responses. Cytokines may modulate the intensity of tissue injury and inflammation in GVHD, and therefore cytokine polymorphisms in either patient or donor or both may explain individual risks of GVHD (review by Petersdorf and Malkki, 2006). (614395)

MalaCards based summary : Graft-Versus-Host Disease, also known as graft-versus-host disease, susceptibility to, is related to chronic graft versus host disease and acute graft versus host disease. An important gene associated with Graft-Versus-Host Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Graft-versus-host disease and Innate Immune System. The drugs Lomustine and Posaconazole have been mentioned in the context of this disorder. Affiliated tissues include Bone, bone marrow and t cells, and related phenotypes are elevated hepatic transaminase and skin erosion

KEGG : 36 Graft-versus-host disease (GVHD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT) where immunocompetent donor T cells attack the genetically disparate host cells. GVHD pathophysiology can be summerized in a three-step process. Step 1 involves the development of an inflammatory milieu resulting from damage in the host tissues induced by the preparative chemotherapy or radiotherapy regimen. Damaged tissues secrete inflammatory cytokines, including interleukin 1 (IL-1), and tumor necrosis factor (TNF-alpha ). During step 2, antigen-presenting cells (APCs) trigger the activation of donor-derived T cells, which induce further T-cell expansion, induce cytotoxic T lymphocytes (CTL) and natural killer (NK) cells responses and prime additional mononuclear phagocytes to produce TNF-alpha and IL-1. Also, nitric oxide (NO) is produced by activated macrophages, and it may contribute to the tissue damage seen during step 3. During step 3, the effector phase, activated CTL and NK cells mediate cytotoxicity against target host cells through Fas-Fas ligand interactions and perforin-granzyme B.

Wikipedia : 74 Graft-versus-host disease (GvHD) is a syndrome, characterized by inflammation in different organs, with... more...

Related Diseases for Graft-Versus-Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Graft-Versus-Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1106)
# Related Disease Score Top Affiliating Genes
1 chronic graft versus host disease 35.5 IL1A IL10 IFNG
2 acute graft versus host disease 34.5 TNF IL2 IL10 IFNG FASLG ARHGAP45
3 bronchiolitis obliterans 33.2 TNF IL6 IL10 IFNG GZMB
4 bronchiolitis 31.5 TNF IL6 IL1A IL10 IFNG
5 keratoconjunctivitis 31.4 TNF IL6 IL2 IFNG
6 fasciitis 31.2 TNF IL6 IL2 IFNG
7 cystitis 31.2 TNF IL6 IL2 IL1A
8 mucositis 31.2 IL2 IL1B IL10
9 vasculitis 31.2 TNF IL6 IL10 HLA-B
10 localized scleroderma 31.1 TNF IL6 IL2
11 systemic scleroderma 31.1 TNF IL6 IL1B IL10 IFNG
12 exanthem 31.1 TNF IL6 IL2 IL1B IL10 IFNG
13 cutaneous t cell lymphoma 31.0 IL2 IFNG GZMB FAS
14 post-transplant lymphoproliferative disease 31.0 TNF IL6 IL1A IL10
15 lymphoproliferative syndrome 31.0 IL2 IL10 FASLG FAS
16 lichen planus 31.0 TNF IL6 IL2 IL10 IFNG GZMB
17 alopecia 31.0 TNF IL2 IL1B IFNG
18 chickenpox 30.9 TNF IL6 IL2 IL10 IFNG
19 purpura 30.8 TNF IL6 IL10 IFNG
20 diarrhea 30.8 TNF IL6 IL2 IL1B IL10 IFNG
21 ileitis 30.8 TNF IL6 IL10
22 keratitis, hereditary 30.8 TNF IL6 IL1B
23 microscopic polyangiitis 30.7 TNF HLA-DRB1
24 conjunctivitis 30.7 TNF IL6 IL2 IL10 IFNG HLA-B
25 chronic inflammatory demyelinating polyradiculoneuropathy 30.7 IL10 IFNG HLA-DRB1
26 hemolytic anemia 30.7 TNF IL2 IL10 IFNG FASLG
27 lymphopenia 30.7 IL6 IL2 IL10 IFNG FASLG FAS
28 disseminated intravascular coagulation 30.7 TNF IL6 IL10
29 drug reaction with eosinophilia and systemic symptoms 30.7 TNF HLA-B
30 fixed drug eruption 30.6 IL2 IFNG
31 retinal detachment 30.6 TNF IL6 IL10 IFNG
32 bronchitis 30.6 TNF IL6 IL1B IL10
33 polyradiculoneuropathy 30.6 IL10 IFNG HLA-DRB1
34 hemorrhagic cystitis 30.6 TNF IL2 IL1B HLA-A
35 blepharitis 30.6 TNF IL6 IL1B
36 chronic active epstein-barr virus infection 30.6 IL2 IL10 IFNG
37 iridocyclitis 30.5 TNF IL6 IL10 HLA-B
38 gastritis 30.5 TNF IL6 IL1B IL10
39 hand, foot and mouth disease 30.5 IL6 IL10 IFNG
40 respiratory failure 30.5 TNF IL6 IL1B IL10
41 lymphoid interstitial pneumonia 30.5 TNF IL6 IL2
42 frontal fibrosing alopecia 30.4 HLA-B HLA-A
43 encephalitis 30.4 TNF IL6 IL1B IL10
44 cholangitis 30.4 TNF IL6 IL2 IL10 HLA-DRB1 HLA-B
45 osteonecrosis 30.4 TNF IL1B IL10
46 obstructive jaundice 30.4 TNF IL6 IL2
47 epstein-barr virus hepatitis 30.4 HLA-C HLA-B
48 hemophagocytic lymphohistiocytosis 30.4 TNF IL10 IFNG GZMB FAS
49 vascular disease 30.4 TNF IL6 IL2 IL1A IL10 IFNG
50 acute pancreatitis 30.3 TNF IL6 IL1B IL10

Graphical network of the top 20 diseases related to Graft-Versus-Host Disease:



Diseases related to Graft-Versus-Host Disease

Symptoms & Phenotypes for Graft-Versus-Host Disease

Human phenotypes related to Graft-Versus-Host Disease:

58 31 (show all 41)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 elevated hepatic transaminase 58 31 frequent (33%) Frequent (79-30%) HP:0002910
2 skin erosion 58 31 frequent (33%) Frequent (79-30%) HP:0200041
3 diarrhea 58 31 frequent (33%) Frequent (79-30%) HP:0002014
4 oral ulcer 58 31 frequent (33%) Frequent (79-30%) HP:0000155
5 stomatitis 58 31 frequent (33%) Frequent (79-30%) HP:0010280
6 maculopapular exanthema 58 31 frequent (33%) Frequent (79-30%) HP:0040186
7 chronic hepatitis 58 31 frequent (33%) Frequent (79-30%) HP:0200123
8 arthritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001369
9 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
10 irritability 58 31 occasional (7.5%) Occasional (29-5%) HP:0000737
11 skeletal muscle atrophy 58 31 occasional (7.5%) Occasional (29-5%) HP:0003202
12 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
13 pulmonary infiltrates 58 31 occasional (7.5%) Occasional (29-5%) HP:0002113
14 myositis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100614
15 gastrointestinal inflammation 58 31 occasional (7.5%) Occasional (29-5%) HP:0004386
16 jaundice 58 31 occasional (7.5%) Occasional (29-5%) HP:0000952
17 limited elbow movement 58 31 occasional (7.5%) Occasional (29-5%) HP:0002996
18 inflammatory abnormality of the eye 58 31 occasional (7.5%) Occasional (29-5%) HP:0100533
19 hyperbilirubinemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002904
20 tachycardia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001649
21 pneumonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002090
22 hepatosplenomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001433
23 fasciitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100537
24 hemophagocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012156
25 scaling skin 58 31 occasional (7.5%) Occasional (29-5%) HP:0040189
26 elevated alkaline phosphatase 58 31 occasional (7.5%) Occasional (29-5%) HP:0003155
27 limited shoulder movement 58 31 occasional (7.5%) Occasional (29-5%) HP:0006467
28 nausea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002018
29 acute hepatitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0200119
30 recurrent gastroenteritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0031123
31 cutaneous sclerotic plaque 58 31 occasional (7.5%) Occasional (29-5%) HP:0031359
32 lichenoid skin lesion 58 31 occasional (7.5%) Occasional (29-5%) HP:0031452
33 failure to thrive 58 31 very rare (1%) Very rare (<4-1%) HP:0001508
34 lipodystrophy 58 31 very rare (1%) Very rare (<4-1%) HP:0009125
35 trismus 58 31 very rare (1%) Very rare (<4-1%) HP:0000211
36 lymphadenopathy 58 31 very rare (1%) Very rare (<4-1%) HP:0002716
37 dupuytren contracture 58 31 very rare (1%) Very rare (<4-1%) HP:0005679
38 decreased lacrimation 58 31 very rare (1%) Very rare (<4-1%) HP:0000633
39 stiff interphalangeal joints 58 31 very rare (1%) Very rare (<4-1%) HP:0005198
40 recurrent infections 58 Frequent (79-30%)
41 inflammatory abnormality of the skin 58 Very frequent (99-80%)

Clinical features from OMIM:

614395

GenomeRNAi Phenotypes related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 10.25 HLA-A HLA-B HLA-C
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 10.25 HLA-A HLA-B HLA-C
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 10.25 HLA-C
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 10.25 HLA-A HLA-B HLA-C
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 10.25 HLA-A HLA-B HLA-C
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 10.25 HLA-A HLA-B HLA-C
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-202 10.25 HLA-C
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 10.25 HLA-A HLA-B HLA-C
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 10.25 HLA-A HLA-B HLA-C
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.25 HLA-C
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.25 HLA-C
12 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 CD28 HLA-DQB1 IL2
13 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 CD28 FAS FASLG GZMB IL10 IL1A
14 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.77 IL1A
15 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.5 CD28 FAS GZMB IL10 IL1A IL1B
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.5 CD28 FAS GZMB HLA-DQB1 IL10 IL1B

MGI Mouse Phenotypes related to Graft-Versus-Host Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.2 CENPF FAS FASLG HLA-DQB1 IFNG IL10
2 hematopoietic system MP:0005397 10.15 CD28 FAS FASLG HLA-A HLA-DQB1 IFNG
3 endocrine/exocrine gland MP:0005379 10.1 CD28 FAS FASLG HLA-A HLA-DQB1 IFNG
4 immune system MP:0005387 10.1 CD28 FAS FASLG HLA-A HLA-DQB1 IFNG
5 digestive/alimentary MP:0005381 10.09 CD28 FAS FASLG HLA-DQB1 IFNG IL10
6 integument MP:0010771 9.91 CD28 FAS FASLG IFNG IL10 IL1A
7 liver/biliary system MP:0005370 9.76 FAS FASLG HLA-DQB1 IFNG IL10 IL2
8 neoplasm MP:0002006 9.65 CD28 FAS FASLG IFNG IL10 IL1A
9 respiratory system MP:0005388 9.23 FAS FASLG HLA-DQB1 IFNG IL10 IL2

Drugs & Therapeutics for Graft-Versus-Host Disease

Drugs for Graft-Versus-Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 425)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
2
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
3
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
4
Panobinostat Approved, Investigational Phase 4 404950-80-7 6918837
5
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
6
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
7
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
8
Promethazine Approved, Investigational Phase 4 60-87-7 4927
9
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
10
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
13
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
14
Simethicone Approved Phase 4 8050-81-5
15
Povidone Approved Phase 4 9003-39-8
16
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
17
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
18
Semustine Experimental, Investigational Phase 4 13909-09-6
19
Treosulfan Investigational Phase 4 299-75-2 9296
20 Antiprotozoal Agents Phase 4
21 Antiparasitic Agents Phase 4
22 Olive Phase 4
23 Chlorhexidine gluconate Phase 4
24 Histone Deacetylase Inhibitors Phase 4
25 Ergocalciferols Phase 4
26 Vitamin D2 Phase 4
27 Hydroxycholecalciferols Phase 4
28 Hormones Phase 4
29 Hormone Antagonists Phase 4
30 glucocorticoids Phase 4
31 Protective Agents Phase 4
32 Lubricant Eye Drops Phase 4
33 Pharmaceutical Solutions Phase 4
34 Cytochrome P-450 Enzyme Inhibitors Phase 4
35 Cytochrome P-450 CYP3A Inhibitors Phase 4
36 Adjuvants, Immunologic Phase 4
37
Hydroxyitraconazole Phase 4
38 Antacids Phase 4
39 Anti-Ulcer Agents Phase 4
40 Aluminum hydroxide, magnesium hydroxide, drug combination Phase 4
41 Viscosupplements Phase 4
42 Plasma Substitutes Phase 4
43 Blood Substitutes Phase 4
44
Budesonide Approved Phase 3 51333-22-3 63006 5281004
45
Basiliximab Approved, Investigational Phase 3 152923-56-3, 179045-86-4
46
Hydroxychloroquine Approved Phase 3 118-42-3 3652
47
Aldesleukin Approved Phase 2, Phase 3 85898-30-2, 110942-02-4
48
Clobetasol Approved, Experimental, Investigational Phase 3 25122-41-2, 25122-46-7 32798 5311051
49
tannic acid Approved Phase 3 1401-55-4
50
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337

Interventional clinical trials:

(show top 50) (show all 1828)
# Name Status NCT ID Phase Drugs
1 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
2 Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Unknown status NCT02677181 Phase 4 ATG;CsA;mycophenolate mofetil;Methotrexate
3 Anti-thymocyte Globulins for GVHD Prophylaxis After HLA-matched Sibling Stem Cell Transplantation in Patients at 40 Years of Age or More With Hematological Malignancies Unknown status NCT01856803 Phase 4 anti thymoglobulin
4 A Phase IV, Open-label, Prospective, Multicenter Study of the Efficacy and Safety of Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
5 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
6 A Historically-controlled, Multi-center Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule, Prograf Injection) and Methotrexate Combination Therapy for Prevention of GVHD in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
7 Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
8 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Completed NCT02805946 Phase 4 posaconazole
9 Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors Completed NCT02412423 Phase 4 post-transplantation cyclophosphamide
10 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
11 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
12 A Post Marketing Surveillance Looking at Safety of Rapamune (Sirolimus) in Indian Population Undergoing de Novo Renal Transplantation. Completed NCT00195481 Phase 4 Rapamune
13 An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor Completed NCT00044720 Phase 4 Rapamune
14 Management of Pain in Oral Lichen Planus Patients: A Comparative Pilot Study Completed NCT03572959 Phase 4 0.1 % topical triamcinolone acetonide
15 A Randomized, Open-label and Multicenter Trial Comparing Withdrawal of Steroids or Tacrolimus From Sirolimus-based Immunosuppressive Regimen in de Novo Renal Allograft Recipients Completed NCT00195429 Phase 4 Tacrolimus;Sirolimus;prednisone
16 A Randomized, Open-label Study to Compare the Safety and Efficacy of Cyclosporine Dose Reduction With Cyclosporine Elimination in De Novo Renal Allograft Recipients Receiving Rapamune. Completed NCT00195468 Phase 4 CYCLOSPORINE
17 Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients Completed NCT02968134 Phase 4 Posaconazole
18 A Comparison of PTCy-ATG and ATG Strategy in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Recruiting NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil;Ciclosporin A (CsA);methotrexate (MTX)
19 ATG Used in Allogeneic Hematopoietic Stem Cell Transplantation From HLA-matched Sibling Donor as GVHD Prophylaxis Recruiting NCT04203108 Phase 4 ATG;CsA;MTX;MMF
20 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
21 Shanghai General Hospital Affiliated to Shanghai Jiao Tong University Recruiting NCT03608059 Phase 4 ATG/PTCy;standard ATG;standard PTCy
22 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
23 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
24 Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies Recruiting NCT02386800 Phase 4 ruxolitinib tablets or oral pediatric formulation, panobinostat capsules;ruxolitinib tablets or oral pediatric formulation
25 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Enrolling by invitation NCT03176849 Phase 4
26 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
27 A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation Not yet recruiting NCT03190733 Phase 4 ATG
28 The Prophylactic Use of Topical Cyclosporine A 0.05% (Restasis) to Prevent Onset and Progression of Graft-versus-host Disease-related Dry Eye Terminated NCT00553735 Phase 4 Cyclosporine A 0.05%;Arificial Tear
29 Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01282879 Phase 4 Itraconazole
30 An Adaptive Design, Single-Blind, Randomized, Controlled Study Investigating Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel (Gelclair®) in Comparison to Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash ("Magic Mouthwash") for the Management of Oral Mucositis Associated With High Dose Chemotherapy and Methotrexate in Allogeneic Stem Cell Transplant Recipients Terminated NCT03490396 Phase 4
31 Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients Withdrawn NCT03963999 Phase 4 Contrast Enhanced Ultrasound (CEUS)
32 Treatment of of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells. A Phase III Randomized Open Label Multi-center Study in Southern China. Unknown status NCT02291770 Phase 3
33 Extracorporeal Photopheresis for Steroid-refractory Acute GVHD in Children and Young Adults: a Safety and Feasibility Study. Unknown status NCT00179855 Phase 2, Phase 3
34 Mesenchymal Stem Cells Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation Unknown status NCT02241018 Phase 2, Phase 3 CD25 monoclonal antibody;calcineurin inhibitors
35 Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3 filgrastim
36 Phase Ⅱ/Ⅲ Clinical Trial, Multicenter, Randomized, Controlled, for the Evaluation of Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells in Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3 Cyclosporine and Glucocorticoid
37 The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
38 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor HCT Unknown status NCT02178683 Phase 3 Tacrolimus and MMF.
39 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
40 Mesenchymal Stem Cells With or Without G-CSF Mobilized Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplant Unknown status NCT02240992 Phase 2, Phase 3
41 Randomized, Prospective, Multicenter Study to Compare Enteral Nutrition to Parenteral Nutrition as Feeding Support in Patients Presenting Malignant Hemopathy Who Underwent an Allogeneic Hematopoietic Stem Cell Transplantation. Unknown status NCT01955772 Phase 3 Enteral nutrition alanyl-glutamin, Dipeptiven
42 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3 Conditioning regimen;Graft-versus-host disease (GVHD) prophylaxis
43 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
44 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
45 Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Unknown status NCT00619879 Phase 3 Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients;Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies
46 Hemophagocytic Lymphohistiocytosis Unknown status NCT00334672 Phase 3 busulfan;cyclophosphamide;cyclosporine;dexamethasone;etoposide;methotrexate;mycophenolate mofetil;therapeutic hydrocortisone
47 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
48 Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition to Anti-thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Adult Acquired Aplastic Anemia Unknown status NCT01145976 Phase 3 Cy-ATG;Flu-ATG
49 A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation Unknown status NCT00450450 Phase 3
50 Efficacy and Safety of Orale Budesonide in the Prevention of Acute Gastrointestinal Graft-versus-host Disease Following Allogenic Stem Cell Transplantation Completed NCT00180089 Phase 3 Budesonide

Search NIH Clinical Center for Graft-Versus-Host Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Daclizumab
Methylprednisolone
methylprednisolone acetate
Methylprednisolone Sodium Succinate
Muromonab-CD3
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Prednisone
PREDNISONE PWDR
Tacrolimus
Thalidomide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Graft-Versus-Host Disease cell therapies at LifeMap Discovery.

Genetic Tests for Graft-Versus-Host Disease

Genetic tests related to Graft-Versus-Host Disease:

# Genetic test Affiliating Genes
1 Graft-Versus-Host Disease, Susceptibility to 29 IL10

Anatomical Context for Graft-Versus-Host Disease

MalaCards organs/tissues related to Graft-Versus-Host Disease:

40
Bone, Bone Marrow, T Cells, Myeloid, Liver, Skin, B Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Graft-Versus-Host Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Graft-Versus-Host Disease

Articles related to Graft-Versus-Host Disease:

(show top 50) (show all 21779)
# Title Authors PMID Year
1
Genetics of risk factors for graft-versus-host disease. 54 56 61
16412785 2006
2
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. 56 61 54
14657427 2003
3
A protective gene for graft-versus-host disease. 56 61
14657422 2003
4
Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. 56
9162098 1997
5
Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. 54 61
19965675 2010
6
Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease. 61 54
20025985 2010
7
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. 61 54
20160060 2010
8
CCR5 expression on cells from HLA-matched unrelated marrow donors and graft-versus-host disease. 54 61
20053336 2010
9
Soluble lymphotoxin is an important effector molecule in GVHD and GVL. 61 54
19789388 2010
10
Expression of CD62L on donor CD4(+) T cells in allografts: correlation with graft-versus-host disease after unmanipulated allogeneic blood and marrow transplantation. 61 54
19462221 2009
11
High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. 61 54
19159415 2009
12
Association of IL-10 and IL-10Rbeta gene polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling donor. 54 61
19409109 2009
13
Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. 54 61
19221040 2009
14
Ex vivo inhibition of NF-kappaB signaling in alloreactive T-cells prevents graft-versus-host disease. 54 61
19260829 2009
15
Donor treatment with a multipegylated G-CSF maximizes graft-versus-leukemia effects. 61 54
19135951 2009
16
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. 54 61
18614760 2008
17
Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients. 61 54
18541194 2008
18
Interleukin-10 gene polymorphism in bone marrow transplant recipients. 54 61
18405249 2008
19
Extracorporeal photopheresis affects co-stimulatory molecule expression and interleukin-10 production by dendritic cells in graft-versus-host disease patients. 54 61
18234053 2008
20
PECAM-1 polymorphism affects monocyte adhesion to endothelial cells. 54 61
18301339 2008
21
[Donor lymphocyte infusion for treatment of relapse of leukemia after HLA-mismatched hematopoietic stem cell transplantation]. 54 61
18681305 2008
22
Importance of interleukin-7 in the development of experimental graft-versus-host disease. 54 61
18158957 2008
23
IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. 61 54
18021367 2007
24
Single nucleotide polymorphism of CC chemokine ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host disease and its severity after allogeneic transplantation. 54 61
17984846 2007
25
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. 54 61
17889355 2007
26
Absence of cutaneous TNFalpha-producing CD4+ T cells and TNFalpha may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. 54 61
17429441 2007
27
Granulocyte colony-stimulating factor for the induction of T-cell tolerance. 54 61
17632408 2007
28
A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403. 61 54
17496542 2007
29
Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. 61 54
17331846 2007
30
Expression of CCR5 in graft-versus-host disease (GVHD) of the skin: immunohistochemical staining of 38 cases. 61 54
17352723 2007
31
Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. 61 54
16937391 2007
32
Interleukin-18 and the pathogenesis of inflammatory diseases. 61 54
17336692 2007
33
CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. 54 61
17145599 2006
34
Role of non-HLA genetic polymorphisms in graft-versus-host disease after haematopoietic stem cell transplantation. 54 61
16984283 2006
35
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. 61 54
16864058 2006
36
Effect of interleukin-15 on alloreactivity in umbilical cord blood. 61 54
16860714 2006
37
DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens. 54 61
16707472 2006
38
No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF. 54 61
16646673 2006
39
Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. 54 61
16123384 2006
40
Genomic polymorphism and allogeneic hematopoietic transplantation outcome. 61 54
16399580 2006
41
Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis. 54 61
16367941 2006
42
Daclizumab for children with corticosteroid refractory graft-versus-host disease. 61 54
16247417 2006
43
Cytokine-mediated signalling and early defects in lymphoid development. 61 54
16264332 2005
44
Simultaneous control of third-degree graft-versus-host disease and prevention of recurrence of juvenile myelomonocytic leukemia (JMML) with 6-mercaptopurine following fulminant JMML relapse early after KIR-mismatched bone marrow transplantation. 61 54
16344675 2005
45
Interleukin-18 treatment options for inflammatory diseases. 61 54
20477603 2005
46
The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions. 54 61
16219576 2005
47
IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. 61 54
15976176 2005
48
Prospective monitoring of tumor necrosis factor alpha and interferon gamma to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. 54 61
16125641 2005
49
Haplotype mismatched transplantation using high doses of peripheral blood CD34+ cells together with stratified conditioning regimens for high-risk adult acute myeloid leukemia patients: a pilot study in a single Korean institution. 61 54
15778730 2005
50
Successful unrelated cord blood transplantation in a child with beta-thalassemia major. 61 54
15840763 2005

Variations for Graft-Versus-Host Disease

Copy number variations for Graft-Versus-Host Disease from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 188553 4 66300000 70400000 Absence of gene UGT2B17 Graft versus host disease

Expression for Graft-Versus-Host Disease

Search GEO for disease gene expression data for Graft-Versus-Host Disease.

Pathways for Graft-Versus-Host Disease

Pathways related to Graft-Versus-Host Disease according to KEGG:

36
# Name Kegg Source Accession
1 Graft-versus-host disease hsa05332

Pathways related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 TNF IL6 IL2 IL1B IL1A IL10
2
Show member pathways
13.9 TNF IL6 IL2 IL1B IL1A IL10
3
Show member pathways
13.77 TNF IL6 IL2 IL1B IL1A IL10
4
Show member pathways
13.52 TNF IL6 IL2 IL1B IL1A IL10
5
Show member pathways
13.43 TNF IL6 IL2 IL1B IL1A IL10
6
Show member pathways
13.43 TNF IL6 IL2 IL1B IL1A IL10
7
Show member pathways
13.37 TNF IL6 IL1B IL1A GZMB FASLG
8
Show member pathways
13.29 TNF IL2 IL1B IL1A IFNG HLA-DRB1
9
Show member pathways
13.19 TNF IL6 IL2 IL1B IL10 IFNG
10
Show member pathways
13.13 TNF IL6 IL2 HLA-C HLA-B HLA-A
11
Show member pathways
13.09 TNF IL6 IL1B HLA-C HLA-B HLA-A
12
Show member pathways
13.01 HLA-DRB1 HLA-DQB1 HLA-C HLA-B HLA-A
13 12.9 IL6 IL2 IFNG FASLG FAS
14 12.83 TNF IL1B IL1A FASLG FAS
15
Show member pathways
12.81 TNF IL2 IL10 IFNG HLA-DRB1 HLA-DQB1
16
Show member pathways
12.8 TNF IL1B IL1A IFNG FASLG FAS
17 12.79 TNF IL6 IL1B IFNG HLA-DRB1 HLA-DQB1
18
Show member pathways
12.78 TNF IL6 IL2 IL1B IL1A
19
Show member pathways
12.78 TNF IL6 IL2 IL1B IL1A IL10
20
Show member pathways
12.73 TNF IL6 IL2 IL1B IL10 IFNG
21 12.73 TNF IL2 IL1B IL10 IFNG GZMB
22
Show member pathways
12.7 IFNG HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B
23
Show member pathways
12.68 TNF IL1B IL1A FASLG FAS
24
Show member pathways
12.65 TNF IL2 IFNG HLA-C HLA-B HLA-A
25
Show member pathways
12.65 TNF IL6 IL2 IL1B IL1A IL10
26
Show member pathways
12.54 TNF IL6 IL2 IL1B IL1A IFNG
27 12.5 TNF IL6 IL2 HLA-DRB1 HLA-DQB1 HLA-DPB1
28
Show member pathways
12.46 TNF IL6 IL2 IL1B IFNG
29
Show member pathways
12.45 IL2 HLA-DRB1 HLA-DQB1 CD28
30
Show member pathways
12.43 TNF IL6 IL1B IL1A IFNG
31 12.41 TNF IL6 IL1B FASLG FAS
32
Show member pathways
12.41 TNF IL1B IL1A IL10 IFNG HLA-DRB1
33
Show member pathways
12.4 TNF IL6 IL1B IFNG
34
Show member pathways
12.4 TNF IL6 IL2 IL10
35
Show member pathways
12.4 TNF IL6 IL2 IL1B IL1A IL10
36
Show member pathways
12.38 TNF IL1B IL1A IFNG FASLG FAS
37
Show member pathways
12.37 TNF IL1A GZMB FASLG FAS
38
Show member pathways
12.37 TNF IL6 IL1B IFNG FASLG FAS
39 12.37 TNF IL6 IL1B IL1A IL10 IFNG
40
Show member pathways
12.36 TNF IL6 IL2 IL1B IL10
41 12.33 TNF GZMB FASLG FAS
42 12.33 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A
43 12.32 TNF IL6 IL1B IL1A IL10
44 12.32 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A
45
Show member pathways
12.3 HLA-DRB1 HLA-DQB1 HLA-DPB1 CD28
46 12.3 IL6 IL1A HLA-C HLA-B HLA-A
47
Show member pathways
12.29 TNF IL6 IL2 IL1B IL1A IL10
48 12.21 TNF IL6 IL2 IL1B IL1A IFNG
49 12.2 TNF IL1B IL1A IFNG
50 12.19 TNF IL6 IL2 IL10 IFNG CD28

GO Terms for Graft-Versus-Host Disease

Cellular components related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.1 TNF IL6 IL2 IL1B IL1A IL10
2 integral component of plasma membrane GO:0005887 10.09 TNF HLA-DRB1 HLA-C HLA-B HLA-A FASLG
3 extracellular space GO:0005615 10.09 TNF IL6 IL2 IL1B IL1A IL10
4 Golgi membrane GO:0000139 9.93 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A
5 external side of plasma membrane GO:0009897 9.89 TNF HLA-DRB1 FASLG FAS CD28
6 cell surface GO:0009986 9.81 TNF HLA-DRB1 HLA-DPB1 HLA-C HLA-B HLA-A
7 recycling endosome membrane GO:0055038 9.71 HLA-C HLA-B HLA-A
8 phagocytic vesicle membrane GO:0030670 9.7 HLA-C HLA-B HLA-A
9 endocytic vesicle membrane GO:0030666 9.69 HLA-DRB1 HLA-DQB1 HLA-DPB1
10 transport vesicle membrane GO:0030658 9.65 HLA-DRB1 HLA-DQB1 HLA-DPB1
11 clathrin-coated endocytic vesicle membrane GO:0030669 9.54 HLA-DRB1 HLA-DQB1 HLA-DPB1
12 MHC class II protein complex GO:0042613 9.5 HLA-DRB1 HLA-DQB1 HLA-DPB1
13 MHC class I protein complex GO:0042612 9.43 HLA-C HLA-B HLA-A
14 ER to Golgi transport vesicle membrane GO:0012507 9.43 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A
15 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.1 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A

Biological processes related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.27 TNF IL6 IL2 IL1B IL1A IL10
2 immune system process GO:0002376 10.2 IL2 HLA-DRB1 HLA-DPB1 HLA-C HLA-B HLA-A
3 apoptotic process GO:0006915 10.19 IL1B IL1A IFNG GZMB FASLG FAS
4 negative regulation of apoptotic process GO:0043066 10.15 IL6 IL2 IL10 FAS CD28
5 positive regulation of gene expression GO:0010628 10.14 TNF IL6 IL1B IL1A IFNG CD28
6 adaptive immune response GO:0002250 10.04 IL2 IFNG HLA-DRB1 HLA-DPB1 HLA-C HLA-B
7 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.02 TNF IL1B IL1A HLA-DRB1 FASLG
8 cellular response to lipopolysaccharide GO:0071222 10.01 TNF IL6 IL1B IL1A IL10
9 T cell receptor signaling pathway GO:0050852 10 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-A CD28
10 positive regulation of DNA-binding transcription factor activity GO:0051091 9.99 TNF IL6 IL1B IL10
11 positive regulation of inflammatory response GO:0050729 9.96 TNF IL2 IL1B IFNG
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.94 TNF IL6 IL2 IFNG
13 apoptotic signaling pathway GO:0097190 9.92 TNF FASLG FAS CD28
14 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.91 HLA-C HLA-B HLA-A
15 regulation of insulin secretion GO:0050796 9.91 TNF IL1B IFNG
16 response to glucocorticoid GO:0051384 9.91 TNF IL6 IL10
17 positive regulation of protein phosphorylation GO:0001934 9.91 TNF IL2 IL1B IFNG HLA-DRB1 FAS
18 cytokine-mediated signaling pathway GO:0019221 9.91 TNF IL6 IL2 IL1B IL1A IL10
19 type I interferon signaling pathway GO:0060337 9.9 HLA-C HLA-B HLA-A
20 positive regulation of interleukin-6 production GO:0032755 9.89 TNF IL6 IL1B
21 positive regulation of phagocytosis GO:0050766 9.89 TNF IL1B IFNG
22 positive regulation of nitric oxide biosynthetic process GO:0045429 9.88 TNF IL1B IFNG
23 humoral immune response GO:0006959 9.88 TNF IL6 IFNG CD28
24 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.87 TNF IL1B IL1A
25 positive regulation of JAK-STAT cascade GO:0046427 9.87 TNF IL6 IL10
26 positive regulation of vascular endothelial growth factor production GO:0010575 9.86 IL6 IL1B IL1A
27 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.86 HLA-C HLA-B HLA-A
28 negative regulation of neurogenesis GO:0050768 9.85 TNF IL6 IL1B
29 positive regulation of mitotic nuclear division GO:0045840 9.85 IL1B IL1A CD28
30 extrinsic apoptotic signaling pathway GO:0097191 9.85 TNF IFNG FASLG FAS
31 inflammatory response to antigenic stimulus GO:0002437 9.84 IL1B IL1A HLA-DRB1
32 positive regulation of glial cell proliferation GO:0060252 9.83 TNF IL6 IL1B
33 astrocyte activation GO:0048143 9.82 TNF IL1B IFNG
34 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.81 TNF IL1B IFNG
35 regulation of regulatory T cell differentiation GO:0045589 9.81 IL2 IFNG CD28
36 positive regulation of interleukin-6 secretion GO:2000778 9.81 TNF IL1B IL1A IFNG
37 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.8 TNF IL1B IL10
38 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.78 IL2 IL1B IL1A FAS
39 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.77 IL1B IL1A CD28
40 positive regulation of chemokine biosynthetic process GO:0045080 9.77 TNF IL1B IFNG
41 positive regulation of cytokine secretion GO:0050715 9.76 TNF IL1A IL10 IFNG
42 positive regulation of immunoglobulin secretion GO:0051024 9.75 IL6 IL2
43 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.75 HLA-DRB1 HLA-DPB1
44 positive regulation of neuroinflammatory response GO:0150078 9.75 TNF IL6 IL1B
45 negative regulation of amyloid-beta clearance GO:1900222 9.74 TNF IFNG
46 positive regulation of isotype switching to IgG isotypes GO:0048304 9.74 IL2 CD28
47 positive regulation of MHC class II biosynthetic process GO:0045348 9.74 IL10 IFNG
48 negative regulation of lipid storage GO:0010888 9.74 TNF IL6
49 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.74 TNF IFNG
50 detection of bacterium GO:0016045 9.74 HLA-DRB1 HLA-B HLA-A

Molecular functions related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.21 TNF IL6 IL2 IL1B IL1A IL10
2 cytokine activity GO:0005125 9.56 TNF IL6 IL2 IL1B IL1A IL10
3 TAP binding GO:0046977 9.33 HLA-C HLA-B HLA-A
4 MHC class II receptor activity GO:0032395 9.32 HLA-DRB1 HLA-DQB1
5 peptide antigen binding GO:0042605 9.1 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A

Sources for Graft-Versus-Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....